18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging

18F-FDG metabolic tumor volume (MTV) and total glycolytic activity (TGA) have been proposed as potential prognostic imaging markers for patient outcome in human solid tumors. The purpose of this study was to establish whether MTV and TGA add prognostic information to clinical staging in patients with oral and oropharyngeal squamous cell carcinomas (SCCs). Methods: The Institutional Review Board approved this Health Insurance Portability and Accountability Act–compliant single-institution retrospective study. Forty-five patients with histologically proven oral or oropharyngeal SCC underwent PET/CT for initial cancer staging and were included in the study. MTV was measured using a gradient-based method (PET Edge) and fixed-threshold methods at 38%, 50%, and 60% of maximum standardized uptake value (SUV). The TGA is defined as MTV × mean SUV. Bland–Altman analysis was used to establish the reliability of the methods of segmentation. Outcome endpoints were overall survival (OS) and progression-free survival. Cox proportional hazards univariate and multivariate regression analyses were performed. Results: In Cox regression models, MTV and TGA were the only factors significantly associated with survival outcome after adjusting for all other covariates including American Joint Committee on Cancer (AJCC) stage, with hazards ratio of 1.06 (95% confidence interval, 1.01–1.10; P = 0.006) and 1.00 (95% confidence interval, 1.00–1.01; P = 0.02). The model fit was significantly better when MTV was added to AJCC stage in model I (χ2 value change, 1.16–6.71; P = 0.01) and when TGA was added to AJCC stage in model II (χ2 value change, 1.16–4.37; P = 0.04). The median cutoff point of 7.7 mL for primary tumor MTV was predictive of time to OS (log rank P = 0.04). The median cutoff point of 55 g for PET Edge primary tumor TGA was predictive of time to OS (log rank P = 0.08), though the result was not statistically significant. Conclusion: Gradient-based segmentations of primary tumor MTV and TGA are potential 18F-FDG markers for time to survival in patients with oral and oropharyngeal SCC and may provide prognostic information in addition to AJCC stage. These exploratory imaging markers need validation in larger cohort studies.

[1]  R. B. Jong,et al.  Staging and prognosis in head and neck cancer. , 2009 .

[2]  Anne Bol,et al.  A gradient-based method for segmenting FDG-PET images: methodology and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Truong,et al.  Fluorodeoxyglucose–Positron-Emission Tomography Imaging of Head and Neck Squamous Cell Cancer , 2010, American Journal of Neuroradiology.

[4]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[5]  M. Truong,et al.  Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. , 2012, AJR. American journal of roentgenology.

[6]  Mohamed Allaoua,et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Eskola,et al.  Early Treatment Response Evaluation in Patients with Diffuse Large B-Cell Lymphoma—A Pilot Study Comparing Volumetric MRI and PET/CT , 2011, Molecular Imaging and Biology.

[8]  T. Yen,et al.  PET and PET/CT of the Neck Lymph Nodes Improves Risk Prediction in Patients with Squamous Cell Carcinoma of the Oral Cavity , 2011, The Journal of Nuclear Medicine.

[9]  R. Boellaard,et al.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Paul N. Span,et al.  Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Kristin D. Brockway,et al.  What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. , 2012, International journal of radiation oncology, biology, physics.

[12]  Quynh-Thu Le,et al.  Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Quynh-Thu Le,et al.  Metabolic tumor burden predicts for disease progression and death in lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[14]  S. Larson,et al.  Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[15]  Byung-Joo Lee,et al.  Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy , 2010, Acta oncologica.

[16]  Aswin L Hoffmann,et al.  Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[17]  H. Minn,et al.  Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  Quynh-Thu Le,et al.  Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. , 2012, Clinical lung cancer.

[19]  Reubendra Jeganathan,et al.  Does pre-operative estimation of oesophageal tumour metabolic length using 18F-fluorodeoxyglucose PET/CT images compare with surgical pathology length? , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  A. Ozonoff,et al.  Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. , 2010, Radiology.

[21]  Baosheng Li,et al.  Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  V. Rousson,et al.  Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT , 2007, Acta oncologica.

[23]  M. Kaplan,et al.  Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  A. Cellier Social Security Death Index , 2010 .

[25]  Florent Tixier,et al.  Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  Mohamed Allaoua,et al.  Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. , 2004, International journal of radiation oncology, biology, physics.

[27]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[28]  U. Haberkorn,et al.  High 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) uptake measured by positron emission tomography is associated with reduced overall survival in patients with oral squamous cell carcinoma. , 2009, Oral oncology.

[29]  R. J. Baatenburg de Jong,et al.  Staging and prognosis in head and neck cancer. , 2009, Oral oncology.